Wall Street analyst estimates for Neurocrine Biosciences, Inc. (NBIX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 32 |
| Hold | 5 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 37 |
| Avg rating (1-5) | 0.86 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-10-27 | $1.92 | ||
| 2026-07-30 | $1.39 | $1.65 | -15.8% |
| 2026-05-05 | $1.94 | $1.22 | +59.0% |
| 2026-02-11 | $1.88 | $1.80 | +4.4% |
| 2025-10-28 | $2.04 | $1.58 | +29.1% |
| 2025-07-30 | $1.06 | $0.98 | +8.2% |
| 2025-05-05 | $0.08 | $0.54 | -85.0% |
| 2025-02-06 | $1.00 | $1.62 | -38.3% |
Valuation Ratios
| P/E Ratio | 20.31 |
| Price / Book | 3.92 |
| EV / EBITDA | 15.87 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15.0M | $161.6M | $451.2M | $788.1M | $1.05B | $1.13B | $1.49B | $1.89B | $2.36B | $2.86B |
| Cost of Revenue | 0 | $1.3M | $4.9M | $7.4M | $10.1M | $14.3M | $23.2M | $39.7M | $34.0M | $52.1M |
| Gross Profit | $15.0M | $160.4M | $446.3M | $780.7M | $1.04B | $1.12B | $1.47B | $1.85B | $2.32B | $2.81B |
| Research & Development | $94.3M | $91.8M | $155.8M | $200.0M | $275.0M | $328.1M | $463.8M | $565.0M | $731.1M | $1.02B |
| Selling, General & Admin | $68.1M | $169.9M | $248.9M | $354.1M | $433.3M | $583.3M | $752.7M | $887.6M | $1.01B | $1.16B |
| Operating Expenses | $162.4M | $291.7M | $409.5M | $708.4M | $872.8M | $1.02B | $1.22B | $1.60B | $1.75B | $2.19B |
| Operating Income | -$147.4M | -$131.4M | $36.8M | $72.3M | $163.0M | $102.5M | $249.0M | $250.9M | $570.5M | $619.1M |
| EBITDA | -$139.6M | -$120.6M | $56.3M | $85.9M | $148.1M | $138.1M | $236.6M | $416.1M | $639.7M | $666.6M |
| Interest Expense | 0 | $19.5M | $30.5M | $32.0M | $32.8M | $25.8M | $7.1M | $4.6M | $126.6M | 0 |
| Pre-tax Income | -$141.1M | -$142.5M | $21.8M | $46.5M | $106.7M | $101.4M | $213.9M | $332.1M | $486.0M | $705.4M |
| Income Tax | 0 | 0 | $730,000 | $9.5M | -$300.6M | $11.8M | $59.4M | $82.4M | $144.7M | $226.8M |
| Net Income | -$141.1M | -$142.5M | $21.1M | $37.0M | $407.3M | $89.6M | $154.5M | $249.7M | $341.3M | $478.6M |
| EPS | $-1.63 | $-1.62 | $0.22 | $0.40 | $4.37 | $0.95 | $1.61 | $2.56 | $3.40 | $4.81 |
| EPS (Diluted) | $-1.63 | $-1.62 | $0.22 | $0.39 | $4.16 | $0.92 | $1.56 | $2.47 | $3.29 | $4.67 |
| Shares Outstanding (Diluted) | $86.7M | $88.1M | $95.4M | $95.7M | $97.8M | $97.9M | $98.9M | $101.0M | $103.7M | $102.5M |
Price
| Price | $144.21 |
| Market Cap | $14.5B |
| Exchange | NASDAQ |
| Country | US |
Related companies: COO · ELAN · ICLR · RDY · SMMT · SNN
Explore sector: Healthcare · Biotechnology
More sections of NBIX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks